TRAWNasdaqPharmaceutical PreparationsFiscal year ends December 31
Traws Pharma, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.37−0.00 (-0.76%)
Close on Oct 19, 2026
- Market cap
- $5.81M
- P/E (TTM)
- 0.4
- Dividend yield
- –
Share price
−$2.4935 (−87.19%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Traws Pharma, Inc. grew revenue 1134.5% to $2.79M over fiscal 2025. Free cash flow was -$20.77M.
Revenue
$2.79M
+1134.5% vs. a year earlier
Operating income
-$21.54M
TTM Q2 2026
Free cash flow
-$20.77M
FY2025
EPS, diluted
$0.82
FY2025
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $5.81M
- P/E ratio
- 0.4
- Price to sales
- 2.08
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -357.23%
Fundamentals
- Revenue
- $2.79M
- Net income
- -$21.57M
- EPS, diluted
- $0.82
- Free cash flow
- -$20.77M
- Diluted shares
- 16M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
–
Operating income
-$21.54M
Net income
-$21.57M
EPS, diluted
–
Free cash flow
–
Reported periodTrailing twelve months